Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,604,320
since: 14 May 2006

Abstract: Agomelatine: A novel pharmacological approach to treating depression

posted Friday, 27 November 2009

Drugs Today (Barc). 2009 Aug;45(8):599-608

Agomelatine: A novel pharmacological approach to treating depression

Owen RT.

Medical Information Department, Prous Science, Barcelona, Spain.

Agomelatine is a melatonin analogue which represents a novel class of antidepressants. It acts as an agonist at melatonin MT1 and MT2 receptors and as a specific antagonist at 5-HT2C receptors. It is rapidly absorbed orally and mainly metabolized via CYP1A2 hepatic isoenzymes, has no active metabolites and an elimination half-life of 1-2 hours.

Short-term trials (6-8 weeks) have confirmed the compound's antidepressant effect in major depressive disorder at doses of 25-50 mg/day. It has comparable antidepressant activity to venlafaxine [Effexor®] (75-150 mg/day) and in one trial, showed statistical superiority to sertraline [Zoloft®] 50-100 mg/day. In long-term studies agomelatine was superior to placebo for relapse prevention at 10 months and treatment adherence rates were higher than with venlafaxine and sertraline over 6 months.

The drug has anxiolytic properties and a beneficial effect on sleep without affecting rapid eye movement (REM) activity.

Although agomelatine is generally well tolerated with low adverse event discontinuation rates, it currently requires monitoring of liver function because a small number of patients had raised liver enzyme activities in the trial program.

The compound has fewer effects on sexual function than venlafaxine and, unlike paroxetine [Paxil®], it causes minimal discontinuation symptoms upon abrupt withdrawal.

Agomelatine is currently being investigated for other indications such as seasonal affective disorder, generalized anxiety disorder and bipolar depression.

Source...


Copyright 2009 Prous Science

tags:      

links: digg this    del.icio.us    technorati    reddit